The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Drugs & Targets

EMA grants GSK’227 Orphan Drug Designation for pulmonary neuroendocrine carcinoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

GSK5764227 (GSK’227), a B7-H3-targeted antibody-drug conjugate, has received Orphan Drug Designation from the European Medicines Agency for the treatment of pulmonary neuroendocrine carcinoma, a category of cancer that includes small-cell lung cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Blenrep combination shows OS benefit in MM

GSK plc announced statistically significant and clinically meaningful overall survival results from a planned interim analysis of the DREAMM-7 trial evaluating Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone versus daratumumab in combination with bortezomib plus dexamethasone as a second line or later treatment for relapsed or refractory multiple myeloma. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account